Habermann Thomas M
Department of Hematology, Mayo Clinic College of Medicine, 200 First Street, SW Rochester, MN 55905, USA.
Hematol Oncol Clin North Am. 2006 Oct;20(5):1075-86. doi: 10.1016/j.hoc.2006.06.006.
The evolution and "lessons learned" for therapeutic options and approaches in HCL, which subsequently evolved into the adenosine deaminase inhibitors as the treatment of choice, has been intriguing. The contributions to patient care and individual patient lives have been remarkable. Observation, splenectomy, and recombinant interferon are potential therapeutic are alternatives in select patients as initial therapy, and as therapeutic alternatives in the 10% of patients who have progressive disease after the purine nucleoside analogs.
毛细胞白血病(HCL)治疗选择和方法的演变以及“经验教训”引人关注,其治疗方法后来演变为以腺苷脱氨酶抑制剂作为首选治疗。这些治疗方法对患者护理和个体患者生活的贡献显著。观察、脾切除术和重组干扰素是部分患者初始治疗的潜在替代疗法,也是10%在接受嘌呤核苷类似物治疗后病情进展患者的治疗替代方案。